Dr. Noah Biotech utilizes an AI-driven platform to develop drug combinations specifically targeting orphan diseases, leveraging extensive bio-pharmacological data to identify effective therapeutic options. The company addresses the high failure rates in clinical trials by enhancing drug efficacy and safety through synergistic combinations, ultimately improving treatment outcomes for patients with limited therapeutic options.
Funding
$13.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Developing effective treatments for orphan diseases is challenging due to limited patient populations, a lack of comprehensive biological data, and high failure rates in clinical trials. Traditional drug discovery methods often struggle to identify synergistic drug combinations that can improve efficacy and safety for these rare conditions.
Solution
Dr. Noah Biotech utilizes an AI-driven drug repositioning platform, NOAH's ARK, to identify synergistic drug combinations for orphan diseases. The platform leverages extensive bio-pharmacological data and AI algorithms to predict promising drug combinations that target multiple pathological networks. By identifying synergistic drug partners, Dr. Noah Biotech aims to increase the efficacy of therapeutic effects, reduce toxicity through decreased dosage, and improve treatment outcomes for patients with limited therapeutic options. The company's multi-pronged approach also involves predicting multiple promising indications for a drug candidate at the early development stage to open up new markets and revenue streams.
Target Audience
Dr. Noah Biotech primarily targets pharmaceutical companies and research institutions focused on developing treatments for orphan diseases, as well as patients with rare conditions seeking more effective therapeutic options.
Features
- NOAH's ARK: An AI-driven platform for predicting synergistic drug combinations.
- CombiNet: A solution within ARK that predicts synergistic combinations based on medical and pharmaceutical big data.
- VLab: A solution within ARK that predicts drug mechanisms based on structural data.
- NeuroRG: A high-throughput screening system that analyzes morphological changes in cells using AI to evaluate drug efficacy.
- SF-Rx: A solution within ARK that predicts adverse effects of drug combinations based on clinical data.
- Multi-Strategy Drug Repositioning System: Identifies synergistic drug partners targeting multiple pathological networks.
- Focus on identifying and developing treatments for neurological and muscular system diseases.